Fresenius Medical Care

Conflict Minerals Policy Statement

As the leading manufacturer and provider of dialysis equipment and services, with shares listed on the New York Stock Exchange, Fresenius Medical Care AG & Co. KGaA, together with its subsidiaries (“Fresenius Medical Care”), is subject to the provisions of Section 1502 of the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) relating to “Conflict Minerals.” Section 1502 of the Dodd-Frank Act and SEC Rule 13p-1 addresses the sourcing of 3TG minerals (Tin, Tantalum, Tungsten, and Gold) from the Democratic Republic of the Congo (“DRC”) and adjoining countries (“Covered Countries”) which are known locations where armed groups mine and sell these minerals to finance civil violence.

To better ensure transparency in our supply chain, we are adopting standards in line with the Organization for Economic Co-operation and Development’s (“OECD”) Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas. This will include, but not be limited to, obtaining chain-of-custody declarations from Fresenius Medical Care-sourced and -managed suppliers. It will also include reviews of our relevant supply chain on a regular basis going forward in order to determine the level of supplier compliance with Section 1502 of the Dodd-Frank Act.

Fresenius Medical Care is committed to compliance with Section 1502 of the Dodd-Frank Act and encourages our suppliers to foster similar commitments of their supply chain related to conflict minerals disclosures. Suppliers who are non-compliant with our Conflict Minerals policy shall be reviewed for continued business.